KeyBanc analyst Scott Schoenhaus downgraded Veeva (VEEV) to Sector Weight from Overweight. A recent round of channel checks has indicated that large pharma clients in the middle of software evaluations are leaning towards Salesforce’s (CRM) offering, suggesting more losses than Veeva has outlined, the analyst tells investors in a research note. The firm added that the checks indicate that a healthy number of small and medium businesses have already migrated to Salesforce from Veeva, and it’s becoming clearer that Salesforce is seeing success on its LifeScienceCloud rollout with likely more customer headlines.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva Systems Appoints New Principal Accounting Officer
- Pure Storage, Telus, Hershey, RBC, Veeva: Trending by Analysts
- Morgan Stanley says Salesforce comments show competition ‘heating up’ for Veeva
- Veeva Systems Faces Competitive Threats from Salesforce: Analyst Issues Sell Rating
- Veeva price target lowered to $333 from $341 at Wells Fargo